# colorectal cancer - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 31449
- Completion tokens: 32179
- Reasoning tokens: 16552
- Total tokens: 63628
- API requests reported: 2
- Elapsed seconds: 64.696
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The provided transcriptomic dataset evaluates overall survival (OS) in colorectal cancer (CRC) tumor tissue across 100 statistically significant genes (54 risk-associated with hazard ratio $\text{HR} > 1$, and 46 protective-associated with $\text{HR} < 1$). Integrated biological interpretation reveals a clear functional dichotomy between tumor cell differentiation/metabolic maintenance and stromal-driven invasive remodeling:

1. **Epithelial Lineage Preservation & Mitochondrial Oxidative Metabolism (Protective Axis):** Favorable overall survival ($\text{HR} < 1$) is strongly anchored by colorectal epithelial lineage transcription factors (*CDX2*, *CDX1*), mucosal differentiation markers (*LGALS4*), and a broad network of mitochondrial oxidative phosphorylation (OXPHOS) and TCA cycle enzymes (*NDUFA9*, *ATP23*, *ATP5G1*, *ATP5B*, *CS*, *GLYCTK*, *OGDHL*, *ACSS2*). This indicates that tumors retaining mature colonic epithelial identity and efficient aerobic metabolic machinery display less aggressive clinical behavior.
2. **TGF-$\beta$ Activation, Stromal/ECM Remodeling & EMT (Risk Axis):** Adverse overall survival ($\text{HR} > 1$) is dominated by TGF-$\beta$ superfamily signaling (*INHBB*), mesenchymal long non-coding RNAs (*ZEB1-AS1*), extracellular matrix (ECM) integrin signaling (*ITGBL1*, *ADAMTS18*), and cytoskeletal dynamics (*TPM4*, *MAP1B*, *DCBLD2*). High expression of these features reflects dense stromal reaction, cancer-associated fibroblast (CAF) invasion, and epithelial-mesenchymal transition (EMT).
3. **Oncogenic Survival Signaling & Immunosuppressive Microenvironment (Risk Axis):** Poor survival is further driven by receptor tyrosine kinase / PI3K-AKT signaling hubs (*ABL2*, *AKT3*, *FGF19*) and ecto-nucleotidase mediated immunosuppression (*NT5E*/CD73, *MSLN*), creating a pro-survival microenvironment hostile to effective antitumor immunity.

---

### 2. Core Biological Programs

```
+-------------------------------------------------------------------------------------------------------------------------+
|                                              CORE BIOLOGICAL PROGRAMS                                                   |
+------------------------------------+------------+-------------------------------------+---------------------------------+
| Program Name                       | Direction  | Representative Supporting Genes     | Standardized Ontology / Pathway |
+------------------------------------+------------+-------------------------------------+---------------------------------+
| 1. Intestinal Lineage              | Protective | CDX2, CDX1, LGALS4, MYB             | GO:0030018 / KEGG: Colorectal   |
|    & Differentiation               | (HR < 1)   |                                     | Cancer (hsa05210)               |
| 2. Mitochondrial OXPHOS            | Protective | NDUFA9, ATP23, ATP5G1, ATP5B,       | Reactome: Respiratory Electron  |
|    & Carbon Metabolism             | (HR < 1)   | CS, GLYCTK, OGDHL, ACSS2            | Transport (R-HSA-163200)        |
| 3. TGF-beta Signaling & ECM /      | Risk       | INHBB, ZEB1-AS1, ITGBL1, TPM4,      | Reactome: Signaling by TGF-beta |
|    Mesenchymal Remodeling          | (HR > 1)   | DCBLD2, ADAMTS18, MAP1B             | Receptor Complex (R-HSA-170838) |
| 4. RTK / PI3K-AKT Survival         | Risk       | ABL2, AKT3, FGF19, GADD45B          | KEGG: PI3K-Akt Signaling        |
|    Signaling Network               | (HR > 1)   |                                     | Pathway (hsa04151)              |
| 5. Immune Modulation &             | Mixed      | Risk: NT5E, MSLN, MIR31HG           | Reactome: Immunoregulatory      |
|    Antigen Presentation            |            | Protective: TAPBPL, LGALS9, CCL15   | Interactions (R-HSA-198933)     |
+------------------------------------+------------+-------------------------------------+---------------------------------+
```

#### Program 1: Intestinal Lineage & Epithelial Differentiation
* **Prognostic Association:** Protective ($\text{HR} < 1$).
* **Major Supporting Genes:** *CDX2* ($\text{HR} = 0.7478, P = 2.98 \times 10^{-5}, \text{FDR} = 0.03550$), *CDX1* ($\text{HR} = 0.7809, P = 9.33 \times 10^{-5}, \text{FDR} = 0.05735$), *LGALS4* ($\text{HR} = 0.7712, P = 7.85 \times 10^{-5}, \text{FDR} = 0.05123$), *MYB* ($\text{HR} = 0.7706, P = 5.28 \times 10^{-6}, \text{FDR} = 0.01924$).
* **Standardized Pathway:** GO:0030018 (microvillus organization / intestinal epithelial cell differentiation) and KEGG: Colorectal cancer (hsa05210).
* **Biological Rationale:** *CDX2* and *CDX1* are master homeobox transcription factors essential for maintaining colonic epithelial cell identity and lineage commitment. *LGALS4* (galectin-4) stabilizes epithelial cell-cell adhesion in differentiated enterocytes. Coordinated upregulation of these factors signifies well-differentiated tumors with lower invasive capability.
* **Evidence Strength & Limitations:** Strong statistical concordance across input genes and direct literature evidence in CRC (PMID 30631044). A major limitation is that bulk sequencing signal may reflect the overall ratio of epithelial tumor cells to stroma rather than an active cell-intrinsic transcription program alone. External statistical validation was not performed.

#### Program 2: Mitochondrial OXPHOS & Central Carbon Metabolism
* **Prognostic Association:** Protective ($\text{HR} < 1$).
* **Major Supporting Genes:** *NDUFA9* ($\text{HR} = 0.6886, P = 1.11 \times 10^{-6}, \text{FDR} = 0.00865$), *ATP23* ($\text{HR} = 0.6885, P = 4.85 \times 10^{-7}, \text{FDR} = 0.00664$), *ATP5G1* ($\text{HR} = 0.7471, P = 8.07 \times 10^{-5}, \text{FDR} = 0.05194$), *ATP5B* ($\text{HR} = 0.7483, P = 9.87 \times 10^{-5}, \text{FDR} = 0.05931$), *CS* ($\text{HR} = 0.7545, P = 3.58 \times 10^{-5}, \text{FDR} = 0.03875$), *GLYCTK* ($\text{HR} = 0.7093, P = 5.95 \times 10^{-6}, \text{FDR} = 0.02034$), *OGDHL* ($\text{HR} = 0.6858, P = 1.52 \times 10^{-4}, \text{FDR} = 0.07443$), *ACSS2* ($\text{HR} = 0.7577, P = 1.04 \times 10^{-4}, \text{FDR} = 0.06021$).
* **Standardized Pathway:** Reactome: Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins (R-HSA-163200); KEGG: Citrate cycle (TCA cycle) (hsa00020).
* **Biological Rationale:** Multiple structural and catalytic components of Complex I (*NDUFA9*), Complex V (*ATP5B*, *ATP5G1*, *ATP23* chaperone; PMID 17135288), the TCA cycle (*CS*, *OGDHL*), and central carbon turnover (*GLYCTK*, *ACSS2*) show protective hazard ratios. Preservation of mitochondrial oxidative phosphorylation indicates metabolic homeostasis, whereas metabolic shift away from OXPHOS correlates with aggressive tumor progression.
* **Evidence Strength & Limitations:** High pathway co-membership across independent metabolic genes. Limitations include potential confounding by tissue hypoxia and necrosis in advanced tumors. External statistical validation was not performed.

#### Program 3: TGF-$\beta$ Signaling & ECM / Mesenchymal Remodeling
* **Prognostic Association:** Risk-associated ($\text{HR} > 1$).
* **Major Supporting Genes:** *INHBB* ($\text{HR} = 1.433, P = 2.00 \times 10^{-8}, \text{FDR} = 0.00109$), *ZEB1-AS1* ($\text{HR} = 1.372, P = 9.83 \times 10^{-7}, \text{FDR} = 0.00865$), *ITGBL1* ($\text{HR} = 1.299, P = 1.96 \times 10^{-5}, \text{FDR} = 0.03061$), *TPM4* ($\text{HR} = 1.364, P = 1.30 \times 10^{-6}, \text{FDR} = 0.00891$), *DCBLD2* ($\text{HR} = 1.408, P = 9.86 \times 10^{-7}, \text{FDR} = 0.00865$), *ADAMTS18* ($\text{HR} = 1.263, P = 6.59 \times 10^{-5}, \text{FDR} = 0.04681$), *MAP1B* ($\text{HR} = 1.327, P = 6.74 \times 10^{-5}, \text{FDR} = 0.04720$).
* **Standardized Pathway:** Reactome: Signaling by TGF-beta Receptor Complex (R-HSA-170838); GO:0030198 (extracellular matrix organization).
* **Biological Rationale:** *INHBB* encodes the activin $\beta_{\text{B}}$ subunit, a TGF-$\beta$ superfamily member. Elevated *INHBB* together with EMT-associated lncRNA *ZEB1-AS1*, integrin-like matrix constituent *ITGBL1*, and cytoskeletal remodeling factors (*TPM4*, *MAP1B*) reflects activated desmoplastic stroma and invasion-promoting matrix turnover.
* **Evidence Strength & Limitations:** *INHBB* exhibits the highest statistical significance in the dataset and is corroborated by functional CRC literature (Europe PMC 41992239). A major limitation is distinguishing cancer-associated fibroblast expression from tumor cell intrinsic transcriptomic changes. External statistical validation was not performed.

#### Program 4: RTK / PI3K-AKT Survival Signaling Network
* **Prognostic Association:** Risk-associated ($\text{HR} > 1$).
* **Major Supporting Genes:** *ABL2* ($\text{HR} = 1.301, P = 1.37 \times 10^{-5}, \text{FDR} = 0.02757$), *AKT3* ($\text{HR} = 1.318, P = 3.61 \times 10^{-5}, \text{FDR} = 0.03875$), *FGF19* ($\text{HR} = 1.291, P = 7.87 \times 10^{-5}, \text{FDR} = 0.05123$), *GADD45B* ($\text{HR} = 1.324, P = 1.14 \times 10^{-4}, \text{FDR} = 0.06300$).
* **Standardized Pathway:** KEGG: PI3K-Akt signaling pathway (hsa04151); Reactome: Signaling by Receptor Tyrosine Kinases (R-HSA-9006934).
* **Biological Rationale:** Non-receptor tyrosine kinase *ABL2*, serine/threonine kinase *AKT3*, and oncogenic growth factor ligand *FGF19* promote cell survival, migration, and resistance to apoptosis. *FGF19* activates FGFR4/PI3K signaling, driving aggressive tumor growth.
* **Evidence Strength & Limitations:** Coherent signal across signal transduction nodes. Limitation: Transcript levels do not capture post-translational phosphorylation status. External statistical validation was not performed.

#### Program 5: Immune Modulation & Antigen Presentation
* **Prognostic Association:** Mixed / Subgroup-dependent.
* **Major Supporting Genes:** Risk: *NT5E* ($\text{HR} = 1.313, P = 4.33 \times 10^{-5}, \text{FDR} = 0.03939$), *MSLN* ($\text{HR} = 1.313, P = 6.10 \times 10^{-5}, \text{FDR} = 0.04507$), *MIR31HG* ($\text{HR} = 1.309, P = 4.21 \times 10^{-7}, \text{FDR} = 0.00664$). Protective: *TAPBPL* ($\text{HR} = 0.7110, P = 4.92 \times 10^{-6}, \text{FDR} = 0.01921$), *LGALS9* ($\text{HR} = 0.7533, P = 5.31 \times 10^{-5}, \text{FDR} = 0.04204$), *CCL15* ($\text{HR} = 0.7528, P = 2.99 \times 10^{-5}, \text{FDR} = 0.03550$).
* **Standardized Pathway:** Reactome: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-HSA-198933).
* **Biological Rationale:** *NT5E* (CD73) converts AMP to immunosuppressive extracellular adenosine (PMID 36480312), conferring poor survival. Conversely, antigen-processing TAP binding protein like (*TAPBPL*) and chemoattractant *CCL15* promote effective immune surveillance and associate with extended overall survival.
* **Evidence Strength & Limitations:** Well-established drug target relevance (*NT5E*, *MSLN*; Europe PMC 42363170). Limitation: Bulk RNA cannot decouple tumor-intrinsic immunosuppression from tumor-infiltrating lymphocyte functional states. External statistical validation was not performed.

---

### 3. Key Genes and Interaction Modules

```
+-----------------------------------------------------------------------------------------------------------------------+
|                                        KEY GENES AND INTERACTION MODULES                                             |
+-------------------+---------------------------------------+-----------------------------+-----------------------------+
| Candidate / Module| Statistical Input Direction           | Program Context             | Relationship Type           |
+-------------------+---------------------------------------+-----------------------------+-----------------------------+
| 1. INHBB          | HR=1.433, P=2.00e-8, FDR=0.00109      | TGF-beta / ECM Remodeling   | Regulatory & Pathway        |
| 2. CDX2 / CDX1    | CDX2: HR=0.7478, P=2.98e-5, FDR=0.0355| Epithelial Lineage          | Regulatory Interaction      |
|                   | CDX1: HR=0.7809, P=9.33e-5, FDR=0.0573|                             | (Paralog transcriptional)   |
| 3. ATP5B / ATP5G1 | ATP5B: HR=0.7483, P=9.87e-5, FDR=0.059| Mitochondrial OXPHOS        | Direct Physical Interaction |
|    / ATP23        | ATP23: HR=0.6885, P=4.85e-7, FDR=0.006|                             | (Complex V subunits/chap.)  |
| 4. NT5E (CD73)    | HR=1.313, P=4.33e-5, FDR=0.03939      | Immune Suppression          | Putative / Paracrine        |
| 5. FGF19 / AKT3   | FGF19: HR=1.291, P=7.87e-5, FDR=0.051 | RTK / PI3K-AKT Signaling    | Regulatory Signaling        |
|                   | AKT3: HR=1.318, P=3.61e-5, FDR=0.03885|                             | (Ligand-downstream axis)    |
| 6. ITGBL1 / TPM4  | ITGBL1: HR=1.299, P=1.96e-5, FDR=0.030| ECM / Cytoskeleton          | Co-expression               |
|                   | TPM4: HR=1.364, P=1.30e-6, FDR=0.00891|                             | (Mesenchymal remodeling)    |
| 7. TAPBPL         | HR=0.711, P=4.92e-6, FDR=0.01921      | Antigen Presentation        | Pathway Co-membership       |
| 8. MSLN           | HR=1.313, P=6.10e-5, FDR=0.04507      | Tumor Surface Antigen       | Co-expression               |
| 9. ACSS2 / CS     | ACSS2: HR=0.7577, P=1.04e-4, FDR=0.060| Central Carbon Metabolism   | Pathway Co-membership       |
|    / GLYCTK       | CS: HR=0.7545, P=3.58e-5, FDR=0.03875 |                             | (Intermediary metabolism)   |
| 10. ZEB1-AS1      | HR=1.372, P=9.83e-7, FDR=0.00865      | EMT Regulation              | Regulatory Interaction      |
+-------------------+---------------------------------------+-----------------------------+-----------------------------+
```

1. **INHBB (Activin Subunit Beta B):**
   * **Input Data:** $\text{HR} = 1.4332849, P = 1.9993823 \times 10^{-8}, \text{FDR} = 0.0010931622$ (Risk-associated; primary lead lead gene by significance).
   * **Role:** Acts as a major driver ligand in TGF-$\beta$/Smad signaling pathways promoting epithelial-mesenchymal transition, invasive growth, and desmoplasia in colorectal cancer (Europe PMC 41992239).
   * **Relationship:** Regulatory interaction and pathway co-membership with downstream mesenchymal transcription factors (*ZEB1-AS1*) and matrix proteins (*ITGBL1*).

2. **CDX2 / CDX1 Module:**
   * **Input Data:** *CDX2*: $\text{HR} = 0.74776163, P = 2.9849591 \times 10^{-5}, \text{FDR} = 0.035501926$; *CDX1*: $\text{HR} = 0.78085163, P = 9.334722 \times 10^{-5}, \text{FDR} = 0.05734561$ (Protective).
   * **Role:** Master homeodomain transcription factors that enforce intestinal differentiation and repress oncogenic Wnt/$\beta$-catenin signaling (PMID 30631044).
   * **Relationship:** Regulatory interaction (transcriptional activation of colonic differentiation genes like *LGALS4* and downstream repression of stemness programs).

3. **ATP5B / ATP5G1 / ATP23 Mitochondrial Module:**
   * **Input Data:** *ATP23*: $\text{HR} = 0.68848836, P = 4.854559 \times 10^{-7}, \text{FDR} = 0.0066355753$; *ATP5G1*: $\text{HR} = 0.74710246, P = 8.0740846 \times 10^{-5}, \text{FDR} = 0.051935362$; *ATP5B*: $\text{HR} = 0.74828823, P = 9.8706228 \times 10^{-5}, \text{FDR} = 0.059305088$ (Protective).
   * **Role:** Core catalytic subunits (*ATP5B*, *ATP5G1*) and metallopeptidase chaperone (*ATP23*; PMID 17135288) of mitochondrial $F_1F_o$-ATP synthase (Complex V).
   * **Relationship:** Direct physical interaction among structural subunits (*ATP5B*, *ATP5G1*) within the $F_1F_o$ complex and functional chaperone-substrate regulatory interaction with *ATP23*.

4. **NT5E (CD73):**
   * **Input Data:** $\text{HR} = 1.312982, P = 4.3264551 \times 10^{-5}, \text{FDR} = 0.039390717$ (Risk-associated).
   * **Role:** Ecto-5'-nucleotidase that converts extracellular AMP into adenosine, suppressing cytotoxic T lymphocyte and NK cell activity (PMID 36480312).
   * **Relationship:** Indirect / paracrine metabolic signaling relationship with tumor-infiltrating immune cell surface adenosine receptors (A2AR/A2BR).

5. **FGF19 / AKT3 Axis:**
   * **Input Data:** *FGF19*: $\text{HR} = 1.2909143, P = 7.870291 \times 10^{-5}, \text{FDR} = 0.051227162$; *AKT3*: $\text{HR} = 1.3178566, P = 3.614929 \times 10^{-5}, \text{FDR} = 0.038754165$ (Risk-associated).
   * **Role:** *FGF19* binds FGFR4/$\beta$-Klotho to stimulate downstream PI3K-AKT survival and metabolic signaling.
   * **Relationship:** Indirect regulatory signaling axis (receptor tyrosine kinase ligand triggering downstream cytosolic kinase cascades).

6. **ITGBL1 / TPM4 Matrix-Cytoskeleton Module:**
   * **Input Data:** *TPM4*: $\text{HR} = 1.3635104, P = 1.3036583 \times 10^{-6}, \text{FDR} = 0.0089096897$; *ITGBL1*: $\text{HR} = 1.2990094, P = 1.9594582 \times 10^{-5}, \text{FDR} = 0.030609537$ (Risk-associated).
   * **Role:** *ITGBL1* modulates integrin-dependent cell-matrix interactions while *TPM4* (tropomyosin 4) regulates actin filament contractility during cell migration.
   * **Relationship:** Co-expression and functional pathway co-membership in cancer-associated fibroblast activation and cell motility.

7. **TAPBPL (TAP Binding Protein Like):**
   * **Input Data:** $\text{HR} = 0.71101448, P = 4.9189336 \times 10^{-6}, \text{FDR} = 0.019210192$ (Protective).
   * **Role:** Involved in MHC class I antigen loading and stability, facilitating immune recognition.
   * **Relationship:** Pathway co-membership with antigen processing and presentation machinery.

8. **MSLN (Mesothelin):**
   * **Input Data:** $\text{HR} = 1.3129539, P = 6.1001868 \times 10^{-5}, \text{FDR} = 0.045071312$ (Risk-associated).
   * **Role:** Cell-surface glycosylphosphatidylinositol (GPI)-anchored glycoprotein implicated in cellular adhesion and survival, emerging as a therapeutic target in CRC (Europe PMC 42363170).
   * **Relationship:** Co-expression with epithelial tumor antigens; putative physical interaction with mucins (e.g., MUC16).

9. **ACSS2 / CS / GLYCTK Metabolic Module:**
   * **Input Data:** *GLYCTK*: $\text{HR} = 0.70929051, P = 5.9528278 \times 10^{-6}, \text{FDR} = 0.020341929$; *CS*: $\text{HR} = 0.75447917, P = 3.5836705 \times 10^{-5}, \text{FDR} = 0.038754165$; *ACSS2*: $\text{HR} = 0.75770392, P = 1.0351865 \times 10^{-4}, \text{FDR} = 0.06021151$ (Protective).
   * **Role:** *ACSS2* produces acetyl-CoA, *CS* initiates the TCA cycle, and *GLYCTK* feeds glycerate into glycolytic/gluconeogenic pathways.
   * **Relationship:** Pathway co-membership in central carbon and energy precursor metabolite generation.

10. **ZEB1-AS1 (ZEB1 Antisense RNA 1):**
    * **Input Data:** $\text{HR} = 1.3719515, P = 9.8292748 \times 10^{-7}, \text{FDR} = 0.0086471166$ (Risk-associated).
    * **Role:** Epigenetic long non-coding RNA regulator that transactivates *ZEB1* expression to promote EMT and metastatic dissemination.
    * **Relationship:** Direct epigenetic / transcriptional regulatory interaction with *ZEB1*.

---

### 4. Validation Priorities

```
+-------------------------------------------------------------------------------------------------------------------------+
|                                                 VALIDATION PRIORITIES                                                   |
+--------------------------------+--------------------+--------------------------------+--------------------+-------------+
| Priority Target / Hypothesis   | Category           | Dataset Evidence               | External Evidence  | Status      |
+--------------------------------+--------------------+--------------------------------+--------------------+-------------+
| 1. CDX2/CDX1 Lineage          | Biomarker /        | CDX2 (HR=0.7478, P=2.98e-5),   | Established CRC    | Supported   |
|    Differentiation Axis        | Mechanistic        | CDX1 (HR=0.7809, P=9.33e-5)    | TSG (PMID 30631044)| Hypothesis  |
| 2. INHBB / TGF-beta Mediated   | Therapeutic Target | INHBB (HR=1.433, P=2.00e-8),   | Drives CRC growth  | Supported   |
|    Stromal Aggressiveness      | / Mechanistic      | ITGBL1 (HR=1.299, P=1.96e-5)   | (EurPMC 41992239)  | Hypothesis  |
| 3. Single-Cell & Spatial Stromal| Confounding /     | High covariance of CAF vs      | High CAF heterogeneity| Exploratory |
|    Deconvolution               | Composition Check  | epithelial markers             | in scRNA-seq studies| Hypothesis  |
| 4. NT5E (CD73) Ecto-Nucleotidase| Therapeutic Target | NT5E (HR=1.313, P=4.33e-5,     | Targeted by anti-  | Supported   |
|    Adenosinergic Suppression   |                    | FDR=0.03939)                   | CD73 mAbs (PMID 36480312)| Hypothesis  |
| 5. ATP23-Complex V Assembly    | Network /          | ATP23 (HR=0.6885, P=4.85e-7),  | Metallopeptidase   | Exploratory |
|    & OXPHOS Coupling           | Mechanistic        | ATP5B (HR=0.7483, P=9.87e-5)   | role (PMID 17135288)| Hypothesis  |
+--------------------------------+--------------------+--------------------------------+--------------------+-------------+
```

1. **CDX2 / CDX1 Intestinal Lineage Differentiation Axis**
   * **Category:** Biomarker / Mechanistic hypothesis.
   * **Rationale:** *CDX2* ($\text{HR} = 0.7478$) and *CDX1* ($\text{HR} = 0.7809$) are key markers of colonic epithelial differentiation. Loss of CDX2 expression is associated with aggressive stem-like phenotypes in CRC.
   * **Dataset Evidence:** Strong statistical association with extended OS ($\text{FDR} \le 0.05$).
   * **External Evidence:** Literature confirms CDX2 suppresses Wnt/$\beta$-catenin signaling via GSK-3$\beta$ transactivation in CRC cells (PMID 30631044).
   * **Next Step for Validation:** Immunohistochemical (IHC) tissue microarray (TMA) validation in an independent clinical cohort paired with survival analysis.
   * **Conclusion Status:** Supported hypothesis.

2. **INHBB / TGF-$\beta$ Driven Stromal Invasion & EMT**
   * **Category:** Therapeutic Target / Mechanistic hypothesis.
   * **Rationale:** *INHBB* is the most significant risk gene in the dataset ($\text{HR} = 1.433, P = 2.00 \times 10^{-8}$). Targeted inhibition of activin B signaling may reverse invasion and desmoplasia.
   * **Dataset Evidence:** Highly significant risk association alongside *ITGBL1* and *ZEB1-AS1*.
   * **External Evidence:** Recent studies demonstrate that high INHBB expression drives malignant phenotypes in CRC organoids and mouse models (Europe PMC 41992239).
   * **Next Step for Validation:** Knockdown of *INHBB* in CRC patient-derived organoid (PDO) co-cultures with cancer-associated fibroblasts to assess invasion and drug sensitivity.
   * **Conclusion Status:** Supported hypothesis.

3. **Single-Cell & Spatial Stromal Deconvolution**
   * **Category:** Confounding or composition check.
   * **Rationale:** Bulk tissue transcriptomics convolves tumor cell intrinsic transcripts with infiltrating immune cells and activated stroma.
   * **Dataset Evidence:** Concurrent risk signal from CAF-associated ECM genes (*ITGBL1*, *TPM4*, *ADAMTS18*) and tumor cell genes (*FGF19*, *MSLN*).
   * **External Evidence:** Single-cell RNA sequencing reveals extensive cellular heterogeneity in CRC microenvironments.
   * **Next Step for Validation:** Apply digital cytology deconvolution algorithms (e.g., CIBERSORTx) and spatial transcriptomics to tissue sections to assign signatures to specific cell compartments.
   * **Conclusion Status:** Exploratory hypothesis.

4. **NT5E (CD73) Ecto-Nucleotidase Targeted Immunotherapy**
   * **Category:** Therapeutic target.
   * **Rationale:** *NT5E* ($\text{HR} = 1.313, P = 4.33 \times 10^{-5}$) generates extracellular adenosine, creating an immunosuppressive microenvironment that blunts anti-tumor T cell activity.
   * **Dataset Evidence:** Statistically significant risk association ($\text{FDR} = 0.03939$).
   * **External Evidence:** CD73 is an active clinical drug target with monoclonal antibodies and small-molecule inhibitors in phase I/II trials across solid tumors (PMID 36480312).
   * **Next Step for Validation:** Flow-cytometric evaluation of CD73 protein expression on tumor vs immune cells in fresh CRC tissue dissociation samples, combined with functional adenosine quantification.
   * **Conclusion Status:** Supported hypothesis.

5. **ATP23-Complex V Assembly & OXPHOS Bioenergetics**
   * **Category:** Interaction / network hypothesis.
   * **Rationale:** *ATP23* is a top protective gene ($\text{HR} = 0.6885, P = 4.85 \times 10^{-7}$). It acts as a metallopeptidase and chaperone essential for $F_1F_o$-ATP synthase assembly.
   * **Dataset Evidence:** Strong, consistent protective associations across Complex I (*NDUFA9*) and Complex V (*ATP5B*, *ATP5G1*, *ATP23*).
   * **External Evidence:** Functional genetics in model organisms establish ATP23 as essential for proper ATP synthase complex integration (PMID 17135288).
   * **Next Step for Validation:** Native PAGE gel electrophoresis and immunoprecipitation in CRC cell lines with altered *ATP23* expression to measure OXPHOS complex assembly and oxygen consumption rate (Seahorse assay).
   * **Conclusion Status:** Exploratory hypothesis.

---

### 5. Evidence Grounding

```
+-----------------------------------------------------------------------------------------------------------------------+
|                                                  EVIDENCE GROUNDING                                                   |
+-------------------+--------------------+------------------------+--------------------------+--------------------------+
| Candidate / Theme | Direct Input Data  | Pathway / Ontology     | Network / Protein Inter. | Literature / Clinical    |
+-------------------+--------------------+------------------------+--------------------------+--------------------------+
| INHBB             | HR=1.433, P=2.00e-8| GO: TGF-beta pathway   | STRING: TGFBR network    | CRC aggressiveness       |
|                   | FDR=0.00109        | (Reactome R-HSA-170838)|                          | (Europe PMC 41992239)    |
| CDX2              | HR=0.7478, P=2.98e-5| GO: Intestinal diff.  | Regulatory: Wnt / GSK-3B | Tumor suppressor CRC     |
|                   | FDR=0.03550        | (GO:0030018)           | transactivation          | (PMID 30631044)          |
| ATP23 / ATP5B     | ATP23: HR=0.6885   | Reactome: OXPHOS /     | Complex V physical assembly| Yeast/Human chaperone   |
|                   | ATP5B: HR=0.7483   | ATP synthesis          | (STRING confidence >0.9) | functional role (PMID 17135288)
| NT5E (CD73)       | HR=1.313, P=4.33e-5| Purine metabolism /    | Enzymatic conversion:    | Immunotherapy target     |
|                   | FDR=0.03939        | Immunomodulation       | AMP -> Adenosine         | across cancers (PMID 36480312)
| MSLN              | HR=1.313, P=6.10e-5| Cell surface antigen   | Epithelial co-expression | CAR-T clinical target    |
|                   | FDR=0.04507        |                        |                          | (Europe PMC 42363170)    |
+-------------------+--------------------+------------------------+--------------------------+--------------------------+
```

* **Direct Evidence vs External Evidence:**
  * **Input Dataset Statistics:** Direct evidence is exclusively provided by the uploaded survival table ($\text{HR}$, $P$ value, $\text{FDR}$).
  * **External Statistical Validation:** **External statistical validation was not performed** because no independent validation cohort dataset or replication statistics were supplied.
  * **Database & Literature Evidence:** Functional pathway annotations (Reactome, GO, KEGG), protein interaction databases (STRING), and PubMed literature (e.g., PMID 30631044, Europe PMC 41992239) serve as contextual evidence for biological plausibility. These records do not represent statistical replication of the input dataset.
* **Evidence Independence & Overlap:** Annotations from QuickGO, Reactome, and STRING frequently share underlying primary literature sources and high-throughput experimental databases; they should not be counted as separate validation events.
* **Insufficient Evidence Labels:** Claims proposing direct physical binding between unlinked genes (e.g., *INHBB* directly binding *TPM4*) lack direct protein interaction evidence and are categorized as **insufficient evidence**.

---

### 6. Limitations and Alternative Explanations

1. **Tissue and Cell Composition Confounding (Tumor Purity & Stroma):** Bulk transcriptomic profiling averages expression across tumor cells, cancer-associated fibroblasts (CAFs), endothelial cells, and immune infiltrates. The observed protective effect of epithelial lineage markers (*CDX2*, *LGALS4*) and risk effect of stromal ECM markers (*ITGBL1*, *TPM4*) may reflect overall tumor purity rather than tumor-cell intrinsic transcriptional changes.
   * *Resolution Strategy:* Perform single-cell RNA-seq (scRNA-seq) or immunohistochemical digital imaging analysis to quantify stromal fraction versus tumor cell intrinsic expression.
2. **Absence of Clinical Covariate Adjustment:** Hazard ratios calculated without adjusting for key prognostic variables—such as AJCC tumor stage (Stage I–IV), patient age, microsatellite instability (MSI/MSS) status, or anatomical subsite (right- vs. left-sided colon)—can produce unadjusted confounding.
   * *Resolution Strategy:* Perform multivariable Cox proportional hazards regression incorporating clinical covariates.
3. **Treatment Exposure and Therapy Selection Bias:** Patient survival outcomes are heavily influenced by postoperative adjuvant chemotherapy (e.g., 5-fluorouracil/oxaliplatin). Differences in transcript expression may correlate with treatment responsiveness or resistance rather than baseline tumor biology.
   * *Resolution Strategy:* Perform stratified survival analyses based on adjuvant treatment history.
4. **Post-Translational & Enzymatic Disconnect:** Genes encoding signaling kinases (*AKT3*, *ABL2*) or metabolic enzymes (*CS*, *GLYCTK*, *NT5E*) are evaluated solely at the mRNA level. Transcript abundance does not guarantee active protein expression or enzymatic phosphorylation states.
   * *Resolution Strategy:* Validate protein expression and functional activity using western blotting, phosphoproteomics, and enzymatic assays.
5. **Association vs. Causation Ambiguity:** Observational transcriptomic correlations with overall survival cannot establish direct functional causality. Elevated expression of a risk gene may be a non-causal byproduct of tumor stress responses.
   * *Resolution Strategy:* Conduct functional gain-of-function and loss-of-function experiments (CRISPR knockout / RNAi knockdown) in colorectal cancer cell lines and patient-derived organoids to evaluate direct phenotypic effects on proliferation, invasion, and survival.

External statistical validation was not performed because no independent verification cohort statistics were supplied.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=113, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
